Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Sangamo BioSciences, Inc. (SGMO - Snapshot Report) presented new pre-clinical data from its In Vivo Protein Replacement Platform at the 55th Annual Meeting of the American Society of Hematology (ASH).

The platform is based on Sangamo's zinc finger DNA-binding protein (ZFP) genome-editing technology.

We note that Sangamo is focused on the research, development and commercialization of engineered DNA-binding proteins for the development of novel therapeutic strategies for a range of diseases. This production in turn can provide potential curative treatments for a range of monogenic diseases such as hemophilia and lysosomal storage disorders (LSD) including Gaucher and Fabry disease.

The data demonstrated therapeutic levels of gene modification in non-human primates (NHPs).

The pre-clincial data presented validates the application of genome editing strategy in large animals and suggest that Sangamo can achieve circulating levels of protein above the threshold for therapeutic effect thereby providing a potential cure of a range of monogenic diseases.

Sangamo further optimized its ZFP technology to demonstrate a single systemic treatment which enables stable liver-specific production of replacement protein.

We remind investors that Sangamo has a collaboration agreement with Shire (SHPG - Analyst Report) in 2012 to develop therapeutics for hemophilia, Huntington's disease and other monogenic diseases.

The company has a pipeline of ZFP Therapeutics. The most advanced ZFP Therapeutic candidate, SB-728-T, is being developed for the treatment of HIV/AIDS with data expected later in 2013.

Sangamo currently carries a Zacks Rank #4 (Sell). Some of the better-ranked stocks which look attractive at current levels include Actelion (ALIOF) and Aeterna Zentaris Inc. . Both carry a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GROUP DXYN 15.84 +7.90%
BOFL HOLDING BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%